Key facts
- It has raised $500K across 3 recorded rounds; the latest was Seed Round ($500K) in Oct 2025.
- Notable investors include Impact Assets, Ascendant Venture.
- Bio Usawa has filed 4 Form Ds with the SEC since 2025, most recently Jan 2026 ($500K sold to 7 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Bio Usawa
Funding rounds
3 roundsAbout Bio Usawa
Manufacturer of a biotechnology firm intended to produce lifesaving and affordable monoclonal antibodies. The company develop and regulate the production of monoclonal antibody-based biologic therapies through biosimilar development, quality-controlled manufacturing and local capacity building, enabling healthcare systems in Africa and other underserved markets to access affordable biologic treatments.
- Sector
- Healthcare
- HQ
- San Mateo, CA, United States
- Founded
- 2023
- Employees
- 10
- Website
- biousawa.com/
- Ownership
- Privately Held (backing)
Bio Usawa doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bio Usawa shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bio Usawa in its N-PORT filings yet. We sweep new filings monthly.